Abstract：
UNASSIGNED: To evaluate the efficacy and tolerability of needling/microneedling as an adjunct to NB-UVB phototherapy in the treatment of stable refractory patches of acral vitiligo, based upon clinical and immunohistochemical assessment of melanocyte count and distribution in response to needling/microneedling.
UNASSIGNED: Twenty patients with stable acral vitiligo (≥2 patches) were enrolled. One of the two index patches was randomized to receive needling or microneedling in conjunction with NB-UVB. Patients received phototherapy sessions 3 times weekly, while needling was carried out on biweekly basis for 6 months. Assessment was done clinically using point counting method, VESTA, and global patients\' satisfaction, and immunohistochemically by quantitative assessment of melanocyte count by Melan-A.
UNASSIGNED: No statistically significant difference was observed between NB-UVB monotherapy and either of the combined therapy regimens as regards the mean percentage change in vitiligo surface area (p = .451), mean change in absolute melanocyte count from baseline (p = .589), and mean VESTA (p = .916). Patches subjected to adjuvant microneedling/needling were afflicted by koebnerization in 50% and 20% of cases, respectively.
UNASSIGNED: Neither microneedling nor needling appear to confer an added therapeutic value to NB-UVB phototherapy in the treatment of stable acral vitiligo. Moreover, both carry the risk of koebnerization.
UNASSIGNED: Twenty patients with stable acral vitiligo (≥2 patches) were enrolled. One of the two index patches was randomized to receive needling or microneedling in conjunction with NB-UVB. Patients received phototherapy sessions 3 times weekly, while needling was carried out on biweekly basis for 6 months. Assessment was done clinically using point counting method, VESTA, and global patients\' satisfaction, and immunohistochemically by quantitative assessment of melanocyte count by Melan-A.
UNASSIGNED: No statistically significant difference was observed between NB-UVB monotherapy and either of the combined therapy regimens as regards the mean percentage change in vitiligo surface area (p = .451), mean change in absolute melanocyte count from baseline (p = .589), and mean VESTA (p = .916). Patches subjected to adjuvant microneedling/needling were afflicted by koebnerization in 50% and 20% of cases, respectively.
UNASSIGNED: Neither microneedling nor needling appear to confer an added therapeutic value to NB-UVB phototherapy in the treatment of stable acral vitiligo. Moreover, both carry the risk of koebnerization.
摘要：
未经评估：为了评估针刺/微针作为NB-UVB光疗的辅助治疗的疗效和耐受性，基于对针刺/微针反应的黑素细胞计数和分布的临床和免疫组织化学评估。
未经授权：纳入20例稳定型肢端白癜风患者（≥2个斑块）。将两个索引贴片中的一个随机化以接受与NB-UVB结合的针刺或微针。患者每周接受3次光疗，而针刺每两周进行6个月。临床上使用点计数法进行评估，VESTA,和全球患者满意度，通过Melan-A定量评估黑素细胞计数和免疫组织化学
UNASSIGNED：在白癜风表面积的平均百分比变化（p=.451）方面，NB-UVB单药治疗与任何一种联合治疗方案之间均未观察到统计学上的显着差异，绝对黑素细胞计数相对于基线的平均变化（p=.589），和平均VESTA（p=.916）。在50％和20％的病例中，接受佐剂微针/针刺的斑块受到了koebnerization的影响，分别。
未经证实：在治疗稳定的肢端白癜风中，微针和针刺均未赋予NB-UVB光疗额外的治疗价值。此外，两者都有koebnerization的风险。
未经授权：纳入20例稳定型肢端白癜风患者（≥2个斑块）。将两个索引贴片中的一个随机化以接受与NB-UVB结合的针刺或微针。患者每周接受3次光疗，而针刺每两周进行6个月。临床上使用点计数法进行评估，VESTA,和全球患者满意度，通过Melan-A定量评估黑素细胞计数和免疫组织化学
UNASSIGNED：在白癜风表面积的平均百分比变化（p=.451）方面，NB-UVB单药治疗与任何一种联合治疗方案之间均未观察到统计学上的显着差异，绝对黑素细胞计数相对于基线的平均变化（p=.589），和平均VESTA（p=.916）。在50％和20％的病例中，接受佐剂微针/针刺的斑块受到了koebnerization的影响，分别。
未经证实：在治疗稳定的肢端白癜风中，微针和针刺均未赋予NB-UVB光疗额外的治疗价值。此外，两者都有koebnerization的风险。
